Compare Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF vs Viatris Inc — how do they compare? Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.67 (market cap $7.77B), while Viatris Inc trades at $17.37 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 2.6× Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF's market cap, and Viatris Inc pays a 2.75% dividend while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days and Viatris Inc for 57 Days on average.
| PDBC | VTRS | |
|---|---|---|
Market Cap | $7.77B | $20.03B |
Volume | 6,100,303 | 14,109,977 |
52-Week High | $20.10 | $18.27 |
52-Week Low | $13.16 | $9.74 |
Typical Hold Time | 56 Days | 57 Days |
Sector | — | Health |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PDBC, the Invesco Optimum Yield Diversified Commodity Strategy ETF, trades at $19.66, up 1.29% with strong bullish momentum from moving averages. The ETF has delivered exceptional performance with 45.66% year-to-date gains through Q3 2026, driven by energy and agricultural commodity strength amid geopolitical tensions. Recent institutional activity shows significant position increases despite a 215% surge in short interest in September.
The outlook remains positive given strong commodity trends and defensive positioning benefits, though elevated short interest and RSI levels near overbought territory suggest potential near-term volatility. Commodity exposure provides inflation hedging advantages but remains sensitive to geopolitical developments and global economic conditions.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
